Cordel S, Dupas B, Douillard J Y, Meflah K
INSERM U419, Institut de Biologie, Nantes, France.
Int J Cancer. 1998 Dec 9;78(6):735-9. doi: 10.1002/(sici)1097-0215(19981209)78:6<735::aid-ijc11>3.0.co;2-6.
We studied the effect of immunotherapy using recombinant interleukin-2 (rIL-2) in combination with a differentiating agent, sodium butyrate (NaBut), on experimental 5-fluorouracil (5-FU)-resistant liver metastasis from colorectal cancer in rats. For this purpose, we used direct liver injection of 5-FU resistant cells, PRObRI, in syngeneic BDIX rats to establish liver tumors. The growth of liver metastasis was followed before and after NaBut/rIL-2 treatment by magnetic resonance imaging (MRI). The presence of liver tumors was checked by MRI 7 days after tumor cell injection. Evaluable rats were then assigned randomly to a control and an experimental group. The different treatments were started on day 10 and administered intraperitoneally (i.p.). Combined NaBut/rIL-2 treatment followed by MRI on days 56 and 91 was shown both to significantly reduce the growth of liver tumors and to prevent extrahepatic spread. In addition, NaBut/rIL-2 treatment induced a complete regression in 50% of the rats which remained free of disease.
我们研究了使用重组白细胞介素-2（rIL-2）联合分化剂丁酸钠（NaBut）进行免疫治疗对大鼠实验性5-氟尿嘧啶（5-FU）耐药性结直肠癌肝转移的影响。为此，我们通过向同基因BDIX大鼠直接肝内注射5-FU耐药细胞PRObRI来建立肝肿瘤。在NaBut/rIL-2治疗前后，通过磁共振成像（MRI）跟踪肝转移的生长情况。在肿瘤细胞注射7天后，通过MRI检查肝肿瘤的存在情况。然后将可评估的大鼠随机分为对照组和实验组。在第10天开始进行不同的治疗，并通过腹腔内（i.p.）给药。在第56天和第91天进行MRI检查，结果显示联合使用NaBut/rIL-2治疗既能显著降低肝肿瘤的生长，又能防止肝外扩散。此外，NaBut/rIL-2治疗使50%的大鼠肿瘤完全消退，且这些大鼠无疾病复发。
